Biogen Inc. announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. Dr. Keeney brings more than 20 years of experience leading R&D, business development and strategy organizations at industry-leading companies within biotech and large pharma, most recently as the Chief Executive Officer of NodThera, a clinical stage biotech company advancing a portfolio of NLRP3 inflammasome inhibitors for the treatment of a broad range of inflammatory diseases.

Prior to joining NodThera, Dr. Keeney was at Sanofi where he had responsibility for all of Sanofi Genzyme's business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. Previously, Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at H. Lundbeck A/S. Dr. Keeney holds a Ph.D. in Neuropharmacology from the University of Nottingham, UK and a Bachelor of Science in Neuropsychology from the University of Leeds, UK.